Viatris Quick Ratio 2012-2025 | VTRS
Historical quick ratio values for Viatris (VTRS) over the last 10 years.
| Viatris Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2025-09-30 | $5.84B | $7.36B | 0.79 |
| 2025-06-30 | $5.51B | $7.13B | 0.77 |
| 2025-03-31 | $5.53B | $5.72B | 0.97 |
| 2024-12-31 | $5.67B | $5.78B | 0.98 |
| 2024-09-30 | $7.22B | $7.51B | 0.96 |
| 2024-06-30 | $7.85B | $7.71B | 1.02 |
| 2024-03-31 | $9.10B | $7.76B | 1.17 |
| 2023-12-31 | $9.51B | $7.78B | 1.22 |
| 2023-09-30 | $7.26B | $6.83B | 1.06 |
| 2023-06-30 | $6.14B | $6.52B | 0.94 |
| 2023-03-31 | $5.97B | $6.11B | 0.98 |
| 2022-12-31 | $7.12B | $6.75B | 1.06 |
| 2022-09-30 | $7.11B | $6.52B | 1.09 |
| 2022-06-30 | $7.56B | $7.68B | 0.99 |
| 2022-03-31 | $7.95B | $9.64B | 0.82 |
| 2021-12-31 | $6.93B | $9.88B | 0.70 |
| 2021-09-30 | $7.23B | $10.10B | 0.72 |
| 2021-06-30 | $7.26B | $10.13B | 0.72 |
| 2021-03-31 | $7.38B | $9.98B | 0.74 |
| 2020-12-31 | $7.40B | $10.56B | 0.70 |
| 2020-09-30 | $4.31B | $7.28B | 0.59 |
| 2020-06-30 | $3.68B | $6.97B | 0.53 |
| 2020-03-31 | $3.96B | $5.23B | 0.76 |
| 2019-12-31 | $4.09B | $5.57B | 0.73 |
| 2019-09-30 | $3.88B | $4.65B | 0.84 |
| 2019-06-30 | $3.49B | $4.56B | 0.77 |
| 2019-03-31 | $3.55B | $4.16B | 0.86 |
| 2018-12-31 | $3.79B | $4.59B | 0.83 |
| 2018-09-30 | $3.98B | $5.18B | 0.77 |
| 2018-06-30 | $3.74B | $4.86B | 0.77 |
| 2018-03-31 | $4.12B | $6.39B | 0.65 |
| 2017-12-31 | $4.67B | $6.39B | 0.73 |
| 2017-09-30 | $4.72B | $4.98B | 0.95 |
| 2017-06-30 | $4.36B | $5.17B | 0.84 |
| 2017-03-31 | $4.52B | $4.52B | 1.00 |
| 2016-12-31 | $5.07B | $5.04B | 1.01 |
| 2016-09-30 | $5.28B | $9.55B | 0.55 |
| 2016-06-30 | $10.00B | $3.78B | 2.65 |
| 2016-03-31 | $4.48B | $3.96B | 1.13 |
| 2015-12-31 | $4.52B | $4.12B | 1.10 |
| 2015-09-30 | $4.54B | $3.68B | 1.23 |
| 2015-06-30 | $5.96B | $5.37B | 1.11 |
| 2015-03-31 | $5.52B | $5.29B | 1.04 |
| 2014-12-31 | $4.79B | $5.30B | 0.90 |
| 2014-09-30 | $4.11B | $4.47B | 0.92 |
| 2014-06-30 | $2.69B | $2.60B | 1.03 |
| 2014-03-31 | $2.60B | $2.65B | 0.98 |
| 2013-12-31 | $2.81B | $2.96B | 0.95 |
| 2013-09-30 | $2.70B | $2.56B | 1.05 |
| 2013-06-30 | $2.58B | $2.33B | 1.11 |
| 2013-03-31 | $2.33B | $2.28B | 1.02 |
| 2012-12-31 | $2.38B | $2.19B | 1.08 |
| 2012-09-30 | $2.26B | $2.17B | 1.04 |
| 2012-06-30 | $2.28B | $2.16B | 1.05 |
| 2012-03-31 | $2.25B | $2.11B | 1.07 |
| 2011-12-31 | $2.17B | $2.56B | 0.85 |
| 2011-09-30 | $2.22B | $2.38B | 0.94 |
| 2011-06-30 | $2.35B | $2.52B | 0.93 |
| 2011-03-31 | $2.43B | $2.39B | 1.02 |
| 2010-12-31 | $2.32B | $1.81B | 1.28 |
| 2010-09-30 | $2.24B | $1.72B | 1.30 |
| 2010-06-30 | $2.53B | $1.63B | 1.55 |
| 2010-03-31 | $2.20B | $1.64B | 1.34 |
| 2009-12-31 | $2.17B | $1.72B | 1.26 |
| 2009-09-30 | $2.14B | $1.58B | 1.35 |
| 2009-06-30 | $1.95B | $1.42B | 1.37 |
| 2009-03-31 | $1.89B | $1.34B | 1.41 |
| 2008-12-31 | $2.11B | $1.55B | 1.37 |
| 2008-09-30 | $2.30B | $1.82B | 1.26 |
| 2008-06-30 | $2.33B | $2.11B | 1.10 |
| 2008-03-31 | $2.35B | $2.22B | 1.06 |
| 2007-12-31 | $2.00B | $2.00B | 1.00 |
| 2007-09-30 | $2.19B | $0.77B | 2.85 |
| 2007-06-30 | $2.19B | $0.83B | 2.64 |
| 2007-03-31 | $1.98B | $0.70B | 2.83 |
| 2006-12-31 | $0.96B | $0.29B | 3.36 |
| 2006-09-30 | $1.03B | $0.26B | 3.96 |
| 2006-06-30 | $1.00B | $0.29B | 3.43 |
| 2006-03-31 | $0.91B | $0.27B | 3.44 |
| 2005-12-31 | $0.92B | $0.26B | 3.49 |
| 2005-09-30 | $1.01B | $0.27B | 3.76 |
| 2005-06-30 | $1.31B | $0.26B | 4.94 |
| 2005-03-31 | $1.24B | $0.25B | 5.06 |
| 2004-12-31 | $1.15B | $0.17B | 6.77 |
| 2004-09-30 | $1.12B | $0.17B | 6.69 |
| 2004-06-30 | $1.14B | $0.24B | 4.73 |
| 2004-03-31 | $1.00B | $0.17B | 5.74 |
| 2003-12-31 | $1.02B | $0.25B | 4.13 |
| 2003-09-30 | $0.99B | $0.23B | 4.33 |
| 2003-06-30 | $0.92B | $0.19B | 4.88 |
| 2003-03-31 | $0.99B | $0.27B | 3.73 |
| 2002-12-31 | $1.01B | $0.26B | 3.85 |
| 2002-09-30 | $0.98B | $0.20B | 4.96 |
| 2002-06-30 | $0.88B | $0.17B | 5.17 |
| 2002-03-31 | $0.87B | $0.18B | 4.91 |
| 2001-12-31 | $0.98B | $0.36B | 2.69 |
| 2001-09-30 | $0.89B | $0.36B | 2.48 |
| 2001-06-30 | $0.78B | $0.31B | 2.52 |
| 2001-03-31 | $0.72B | $0.29B | 2.46 |
| 2000-12-31 | $0.61B | $0.27B | 2.27 |
| 2000-09-30 | $0.49B | $0.23B | 2.13 |
| 2000-06-30 | $0.50B | $0.28B | 1.76 |
| 2000-03-31 | $0.54B | $0.09B | 6.16 |
| 1999-12-31 | $0.54B | $0.10B | 5.31 |
| 1999-09-30 | $0.50B | $0.09B | 5.72 |
| 1999-06-30 | $0.48B | $0.11B | 4.53 |
| 1999-03-31 | $0.45B | $0.10B | 4.63 |
| 1998-12-31 | $0.38B | $0.09B | 4.27 |
| 1998-09-30 | $0.34B | $0.09B | 3.92 |
| 1998-06-30 | $0.32B | $0.09B | 3.69 |
| 1998-03-31 | $0.28B | $0.07B | 3.98 |
| 1997-12-31 | $0.26B | $0.07B | 3.94 |
| 1997-09-30 | $0.28B | $0.08B | 3.28 |
| 1997-06-30 | $0.26B | $0.08B | 3.16 |
| 1997-03-31 | $0.28B | $0.08B | 3.53 |
| 1996-12-31 | $0.28B | $0.07B | 3.82 |
| 1996-09-30 | $0.26B | $0.07B | 3.71 |
| 1996-06-30 | $0.28B | $0.06B | 4.75 |
| 1996-03-31 | $0.28B | $0.05B | 5.74 |
| 1995-12-31 | $0.28B | $0.05B | 6.09 |
| 1995-09-30 | $0.26B | $0.04B | 6.63 |
| 1995-06-30 | $0.27B | $0.05B | 5.30 |
| 1995-03-31 | $0.25B | $0.06B | 4.49 |
| 1994-12-31 | $0.22B | $0.05B | 4.15 |
| 1994-09-30 | $0.20B | $0.04B | 5.05 |
| 1994-06-30 | $0.18B | $0.04B | 4.69 |
| 1994-03-31 | $0.15B | $0.02B | 8.46 |
| 1993-12-31 | $0.16B | $0.02B | 6.71 |
| 1993-09-30 | $0.14B | $0.02B | 6.93 |
| 1993-06-30 | $0.14B | $0.03B | 4.79 |
| 1993-03-31 | $0.14B | $0.03B | 5.08 |
| 1992-12-31 | $0.12B | $0.02B | 5.55 |
| 1992-09-30 | $0.10B | $0.03B | 4.11 |
| 1992-06-30 | $0.09B | $0.02B | 4.23 |
| 1992-03-31 | $0.09B | $0.02B | 4.74 |
| 1991-12-31 | $0.07B | $0.02B | 4.29 |
| 1991-09-30 | $0.06B | $0.02B | 4.18 |
| 1991-06-30 | $0.06B | $0.01B | 4.18 |
| 1991-03-31 | $0.06B | $0.01B | 4.85 |
| 1990-12-31 | $0.05B | $0.02B | 3.19 |
| 1990-09-30 | $0.06B | $0.02B | 3.59 |
| 1990-06-30 | $0.05B | $0.01B | 3.92 |
| 1990-03-31 | $0.04B | $0.01B | 5.50 |
| 1989-12-31 | $0.04B | $0.02B | 2.52 |
| 1989-09-30 | $0.04B | $0.01B | 3.71 |
| 1989-06-30 | $0.03B | $0.01B | 3.07 |
| 1989-03-31 | $0.05B | $0.01B | 6.79 |
| 1988-12-31 | $0.05B | $0.01B | 4.21 |
| 1988-09-30 | $0.05B | $0.01B | 4.70 |
| 1988-06-30 | $0.05B | $0.01B | 3.92 |
| 1988-03-31 | $0.05B | $0.01B | 4.72 |
| 1987-12-31 | $0.05B | $0.01B | 3.83 |
| 1987-09-30 | $0.05B | $0.01B | 4.49 |
| 1987-06-30 | $0.05B | $0.01B | 3.99 |
| 1987-03-31 | $0.04B | $0.01B | 6.29 |
| 1986-03-31 | $0.03B | $0.01B | 5.36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $14.812B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $166.691B | 30.61 |
| HCA Healthcare (HCA) | United States | $107.089B | 17.73 |
| CVS Health (CVS) | United States | $99.777B | 11.47 |
| Elevance Health (ELV) | United States | $83.311B | 12.22 |
| Cencora (COR) | United States | $68.839B | 22.19 |
| Natera (NTRA) | United States | $31.987B | 0.00 |
| DiDi Global (DIDIY) | China | $23.485B | 21.70 |
| Labcorp Holdings (LH) | United States | $22.455B | 17.12 |
| Medpace Holdings (MEDP) | United States | $17.208B | 42.72 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.445B | 0.00 |
| BioMerieux (BMXMF) | France | $14.802B | 0.00 |
| ICON (ICLR) | Ireland | $14.747B | 14.63 |
| Solventum (SOLV) | United States | $13.786B | 13.38 |
| Revvity (RVTY) | United States | $12.755B | 23.49 |
| CochLear (CHEOY) | Australia | $11.760B | 0.00 |
| Charles River Laboratories (CRL) | United States | $10.813B | 20.83 |
| Avantor (AVTR) | United States | $8.291B | 12.67 |
| Sonic Healthcare (SKHHY) | Australia | $7.752B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.556B | 0.00 |
| HealthEquity (HQY) | United States | $7.294B | 27.27 |
| BrightSpring Health Services (BTSG) | United States | $7.070B | 42.15 |
| Bausch + Lomb (BLCO) | Canada | $6.078B | 39.91 |
| PACS (PACS) | United States | $6.072B | 36.92 |
| Sotera Health (SHC) | United States | $5.449B | 26.27 |
| Alignment Healthcare (ALHC) | United States | $4.502B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $3.719B | 21.70 |
| GeneDx Holdings (WGS) | United States | $3.124B | 54.86 |
| Concentras Parent (CON) | United States | $2.762B | 17.24 |
| Organon (OGN) | United States | $2.277B | 2.40 |
| Progyny (PGNY) | United States | $2.114B | 41.56 |
| Surgery Partners (SGRY) | United States | $2.057B | 26.50 |
| Establishment Labs Holdings (ESTA) | United States | $1.962B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.877B | 11.21 |
| Ardent Health (ARDT) | United States | $1.231B | 4.02 |
| Teladoc Health (TDOC) | United States | $1.115B | 0.00 |
| Nutex Health (NUTX) | United States | $1.080B | 8.26 |
| CareDx (CDNA) | United States | $1.029B | 16.82 |
| Omada Health (OMDA) | United States | $0.933B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.910B | 14.89 |
| InnovAge Holding (INNV) | United States | $0.794B | 0.00 |
| Embecta (EMBC) | United States | $0.734B | 4.17 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.706B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.594B | 0.00 |
| CryoPort (CYRX) | United States | $0.552B | 0.00 |
| Enhabit (EHAB) | United States | $0.532B | 23.91 |
| Strata Critical Medical (SRTA) | United States | $0.515B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| SBC Medicals (SBC) | United States | $0.445B | 8.19 |
| Agilon Health (AGL) | United States | $0.423B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.343B | 5.51 |
| Oncology Institute (TOI) | United States | $0.330B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.288B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.279B | 58.75 |
| So-Young (SY) | China | $0.269B | 0.00 |
| KindlyMD (NAKA) | United States | $0.201B | 0.00 |
| Beauty Health (SKIN) | United States | $0.191B | 0.00 |
| LifeMD (LFMD) | United States | $0.181B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.141B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.139B | 0.00 |
| DocGo (DCGO) | United States | $0.081B | 0.00 |
| Biodesix (BDSX) | United States | $0.063B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.047B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.046B | 0.00 |
| Pomdoctor - (POM) | China | $0.030B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.020B | 6.21 |
| OSR Holdings (OSRH) | United States | $0.019B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.018B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.016B | 0.00 |
| Lifeward (LFWD) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.003B | 0.00 |
| XWELL (XWEL) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.000B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |